Pickering et al., 2004 - Google Patents
St. George's Hospital Medical School, London, United Kingdom Apomine is a novel 1, 1-bisphosphonate ester that inhibits cholesterol synthesis through mevalonate …Pickering et al., 2004
View PDF- Document ID
- 3012547907371487690
- Author
- Pickering L
- Lowe L
- Ganguli S
- Mansi J
- Colston K
- Publication year
- Publication venue
- British Journal of Cancer
External Links
Snippet
Aims: 1. To examine the suitability of lentiviral vectors (LV), based on the equine infectious anaemia virus (EIAV) and human immunodeficiency virus type-1 (HIV-1) as a gene delivery system for pancreatic cancer gene therapy and compare their efficiency. 2. To deliver and …
- 230000000694 effects 0 title abstract description 45
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Chemokine receptors as targets for cancer therapy | |
| JP2021523110A (en) | Nanoparticles for gene expression and their use | |
| US11788093B2 (en) | Chimeric antigen receptor t-cells expressing interleukin-8 receptor | |
| AU2024203377A1 (en) | Altering inflammatory states of immune cells in vivo by modulating cellular activation states | |
| WO2018085275A1 (en) | Targeting lats1/2 and the hippo intracellular signaling pathway for cancer immunotherapy | |
| Kottke et al. | Subversion of NK-cell and TNFα immune surveillance drives tumor recurrence | |
| Karami Fath et al. | Recent advances in glioma Cancer treatment: conventional and epigenetic realms | |
| Lin et al. | Evaluation of nonviral piggyBac and lentiviral vector in functions of CD19chimeric antigen receptor T cells and their antitumor activity for CD19+ tumor cells | |
| TWI441651B (en) | Use of eif-5a to kill multiple myeloma cells | |
| KR20150014399A (en) | Vitamin B6 coupled gene transporter and cancer gene therapy using the same as a gene carrier | |
| JP2022532303A (en) | FMRP and cancer treatment | |
| Pickering et al. | St. George’s Hospital Medical School, London, United Kingdom Apomine is a novel 1, 1-bisphosphonate ester that inhibits cholesterol synthesis through mevalonate pathway inhibition and mimics the effects of farnesol in vitro. Unlike conventional bisphosphonates, it does not | |
| US20230277668A1 (en) | Chimeric antigen receptor and use thereof | |
| Pickering et al. | ANTI-METASTATIC EFFECTS OF THE BISPHOSPHONATE ESTER APOMINE IN BREAST CANCER CELL LINES IN VITRO | |
| EP4400113A1 (en) | Hypoxia-triggered artificial transcription factor and hypoxia-triggered transcription control system, and application thereof | |
| Kumar et al. | Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles | |
| JP2024536188A (en) | Compositions and methods for anti-TNMUC1 GOLD CAR T cells | |
| Assudani et al. | Immunotherapeutic potential of DISC-HSV and OX40L in cancer | |
| Li et al. | The optimal outcome of suppressing Ewing sarcoma growth in vivo with biocompatible bioengineered miR-34a-5p prodrug | |
| US20220378879A1 (en) | Application of peg interferon and protooncogene product targeting inhibitor in synergistic treatment of renal carcinoma | |
| CN116670172A (en) | Cancer-specific trans-splicing ribozymes expressing immune checkpoint inhibitors and uses thereof | |
| CN115997122A (en) | Method for selecting cancer patients for whom combination therapy of retinoid with cancer therapeutic agent is effective, and combination drug of retinoid with cancer therapeutic agent | |
| CN111419832A (en) | Pharmaceutical composition and application thereof in preparing medicines for treating tumors | |
| KR102471898B1 (en) | Tumor-targeting trans-splicing ribozyme expressing immune checkpoint inhibitor and use thereof | |
| US20230270881A1 (en) | Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer |